CD19 and neoplasm: To further investigate the effects of 25 nM dasatinib, we conducted additional co-culture experiments using CAR19-NK-92 cells and CD19-positive tumor cell lines (Nalm-6 and Raji) at an effector-to-target ratio of 2:1 (Figure 6).